Banerji Protocol Meeting
07 March 2013
In Attendance:
Dr. Iris R Bell
Khadija Ben-Aissa
Anil Srivastava
Peter Gold
Dr. Pratip Banerjee
Dr. Leanna J Standish:
Not in Attendence:
Dr. Shankar Gupta
Charles Maynard
Dr. Shantaram Kane
Rubayi Srivastava
Professor, Department of Family and Community Medicine,
Research Professor, College of Nursing, University of Arizona.
Scientific Program Coordinator, Open Health Systems
Laboratory, Maryland.
President, Open Health Systems Laboratory, Maryland.
expert on media and publicity for the homeopathic
community in the US
The Prasanta Banerji Homeopathic Research Foundation
PhD, Program Director, Pharmaceutical Resources
(PBHRF), Kolkata.
Executive Dir., Open Health Systems Laboratory, Maryland.
Chemical Engineer, Independent Researcher in Ayurveda and
Adjunct Prof at IITBombay
PPP Project Manager, Open Health Systems Laboratory,
California.
Dr. Barbara Sarter
Associate Professor, Hahn School of Nursing and Health
Sciences, University of San Diego, California.
Branch, NCI, National Institute of Health, Maryland.
Topics of Discussion
 Peter Gold will provide a bio.
 Khadija will update the potential collaborators on the wiki
 OHSL will connect with potential collaborators
 Invite Dr. Leanna Standish for our next meeting
 Meeting with Barbra and Koumatsoulis to discuss the new Form.
 Barbara will try to get an answer from MD Anderson investigator about
trying some remedies on cell lines.
Discussion:
Introductions
 Petre: Alison Teitelbaum (National center for Homeopathy Exsecutive
Director) would like to have permission to join the BP discussions.
 Dr. Leanna (http://www.bastyr.edu/people/alumni-facultyresearcher/leanna-j-standish-phd-nd-lac-fabno) had a continuous interest in
the BP way back (~15 years). She is a neuroscientist who had an interest in
Natural medicine combined to chemotherapy and shares a particular interest
with Dr. Iris Bell on the nanoparticle concept of Homeopathic remedies.
She is treating patient and tried using the BP for some of her patients:~12
GM patients accepted to be treated by the BP and have a survival rate of 25
months.
She is practicing in the University of Washington.
 Dr. Peter Gold is treating patients but on limited base
From 2005 he communicate with homeopaths in all over the world except in
Latin America (Group coordination, social media…)
Lotte And John Hecht Memorial Foundation and NCCAM is funding Dr.
Leanna project on Breast cancer integrative oncology Prospective Matched
Controlled Outcomes Study within Bastyr University.
Hecht foundation supports Global advancement.
Banerji Protocol outcome:
 Dr. Leanna: Do the Banerjis have a database of patient treatmet and
outcome? Publishing a formal outcome analysis of the Banerji clinic is a good
start.
 Iris: they have a good online review on Ruta but I don’t know where is it
published. The Banerjis are very committed and open to share data.
 Peter: what does the data show?
 Iris: the outcomes are quiet strong and they helped many people from India
as well as many foreigners. In India it is very common to see patients
combining homeopathy with allo-medicines. The Banerjis say that the
outcome is better with the patients who did not succeed to overcome the
illness with allo-medicine alone.
Applying resources:
 Peter has relationships with multi social media publishers. There are a lot of
ways for exposure to social media but t is preferential to have a scientific
publication first. Iris would be better placed for that.
 Iris: may be we focus our next conference call on data mining_ publishing
reports of clinic outcome.
 Iris/Barbra paper is in the process of review might bring more attention to
this subject once it is published. The focus of the paper is nanoparticles and
will be published in a nanomedecine journal rather that a homeopathy
journal.
 Clinical testing depends on dose, size, nanoparticles. We need to be able to do
Bioassays, clinical studies…
 Iris thinks that it will be possible to publish in a nanomedecine journal, they
will find the topic very interesting.
How to proceed:
 Dr. Leanne How to proceed here:
1. Retrospective outcome, Preliminary
a. Specific focus on Glioblastoma multiform: GBM
b. Publish
2. Find fund for clinical Trial: The Hecht foundation, they will fund a clinical
trial in the United Sates to replicate the Banerjis finding.
a. Dr. Leanna Q: Are the Banerjis open to have a trial here in US
b. Iris: From our discussion when I met him they are very open.
3. Dr. Leanna
a. I already have done a lot of research on GBM
b. I know how to establish the protocol
c. And I have expertise to do imaging for phase 1 and phase 2 trial
d. Did you already have any discussion regarding FDA approval?
4. Critical: how to evaluate the actual material used in the remedies
a. Multiple technology:
i. TEM
ii. Laser based microscopy
iii. Nanoparticle tracking methods. Estimate concentration. The
advantage is that the NP in the homeopathic remedies are
dispersed (variable sizes)
iv. Physical characterization (what are the criteria we are looking
for)
5. Now we can have a chance to prove the mechanism of action of
homeopathic remedies used in a protocol and in response to diagnosis.
a. Before the nanotechnology emergence we did not have any way to
characterize the remedies.
b. Where are the remedies from:Iris: Barbara gets some from the
Banerjis Leanna: do you have sample from them.
c. Looking for nanotechnology experts who can help charachterizing the
nanoparticles in the remedies. Iris tried to contact Dr. Shena Kelly
(http://biochemistry.utoronto.ca/kelley/kelley.html) but did not get
any reply.
d. Iris: commercial vendors: 300$/ sample. San Diego vendor, it takes
from 1h to few days to see results.
e. Peter: we can identify a handful of academic institution to
characterize the core remedies of the BP (Harvard Nanomedecine
department…).
f. Confirm the presence of the NP in the remedies.
g. Iris: Scorpion venom nanoparticle slow down Brain cancer cells
h. Demonstrate that such remedy is active by looking at size and
structure, surface charge…
i. Iris will send a short description the correlations.
Points collected from Khadija discussions with Dr. Barbara Sarter and DR.
Pratip Banerji:
Patient clinical reports and Banerjis database:
 The Banerji clinics keep clinical record using Oracle medical.
 Dr. Barbara was analyzing subsets of the data
 The Indian statistical Institute is analyzing subsets of the Banerji’s clinical
data.
 Although all patient records are kept, not all of the records were digital. The
staff in the clinics are overloaded and not very well trained which influences
the accuracy of the collected patient reports: Lack of correct terminology and
missing information. Dr. Barbara spent some time in the clinics and
succeeded in converting a complicated clinical record form provided by NCI
to a more friendly, which can be easily used by the clinic staff. This intake
sheet (of 1-2 pages) will help the Staff in such very busy clinical environment
to collect more accurate data without loosing accuracy of the information. Dr.
Barbara believes that if the Banerjis implement the use of such form within
one year we will have very accurate clinical reports to analyze.
 Dr. Banerji worked with Dr. Sushanta Banerjee and Dr. Srater on statistical
analyses of \ Brain cancer patient outcomes. The statistical analysis showed
that the best rate of success was observed with the GBM patients treated
with the Banerji protocol. Dr. Barbara compared these results to the
outcome of patients treated by the best conventional medicine using the
SEER database and found that the BP outcomes are superior. The manuscript
is being reviewed and corrected by DR. Sushanta.
Banerji Protocol homeopathic remedies Origin:
 Dr. Sarter doe not have GBM remedies from the Banerji clinics.
 Dr. Banerji is getting his remedies from an Indian manufacture SBL:
http://www.sblglobal.com
For research purpose we can have an agreement to get remedies distributed
to the US.
Action items for next meeting:
1. The group will focus on data mining_ publishing reports of clinic outcome.
2. The group decides for Mrs. Alison Teitelbaum (National center for
Homeopathy Executive Director
http://www.nationalcenterforhomeopathy.org/hta/meet-new-nchexecutive-director-alison-teitelbaum-ms-mph) to join the BP discussions.
3. Iris will send a description of correlation between size, surface charge
and nanoparticle characterization
4. Khadija will send to Dr. Banerji the list mail of all the participants of the
BP. He will send his Book by mail.
5. Khadija will contact Dr. Sushanta Banerjee and get and update about the
Banerji protocol and GBM manuscript.
6. Dr. Barbara will write a draft of summary paper about converting a
complicated clinical record form provided by NCI to a more friendly form
used by the clinic staff in a very busy clinical environment without
loosing accuracy of the information and allowing more accurate scientific
analysis.
7. Dr. Banerji will ask SBL if they distribute in the United State.